Nanobody could be used as antiviral treatment against COVID-19
Researchers have found a nanobody named Ty1 that neutralises SARS-CoV-2 by attaching itself to the Spike protein of COVID-19.
List view / Grid view
Researchers have found a nanobody named Ty1 that neutralises SARS-CoV-2 by attaching itself to the Spike protein of COVID-19.
The UK government will invest £8.4 million in COVID-19 research projects to reveal more information that can be used to develop therapies and vaccines against the disease.
Researchers reveal that activating the MHC class II transactivator (CIITA) and CD74 genes protected cells against infection by Ebola and SARS-CoV-2.
Scientists have patented their technique of inhibiting cellular growth factor signalling to stop SARS-CoV-2 replication and treat COVID-19.
Researchers report that while the spike protein and RNA polymerase proteins have stabilised, other regions of the SARS-CoV-2 genome are becoming increasingly variable.
Scientists have revealed that the cytokines IL-6 and TNF-α are two biomarkers of inflammation that can predict the severity of COVID-19.
Researchers have found that the SARS-CoV-2 nucleocapsid protein may help the virus to spread from cell to cell, providing a drug target.
A drug screen using machine learning has identified hundreds of potential drugs that could be used to treat COVID-19, researchers say.
A possible treatment and vaccine combination for COVID-19 has shown positive results in pre-clinical studies using human cells.
Five immune response biomarkers have been identified by researchers who say they can be used to classify which COVID-19 patients will survive the disease.
Researchers have found the small molecules Apilimod and Vacuolin-1 inhibited the PIKfyve kinase in cells, preventing infection from Zaire ebolavirus and SARS-CoV-2.
A new decoy receptor of ACE2 has been created which binds to and neutralises COVID-19 in live tissue cultures, preventing cells from becoming infected.
According to researchers, drugs that target envelope protein E on the SARS viral membrane could also be used to target a similar protein on COVID-19.
Research has shown T cells taken from patients with COVID-19 target the same three to eight immunodominant epitopes - most of which are not on the Spike protein.
A UK company has announced that their lung epithelium model can successfully be used to test potential treatments for COVID-19.